GlassScriptPhysician profile
Lawrence J Santora
NPI 1982635645
$8,302.59
in general payments reported to CMS, 2019-2025
41 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $636 · 2021: $1,866 · 2022: $1,624 · 2023: $1,192 · 2024: $1,035 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,216.74 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $1,070.34 | 2021-2025 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.99 | 2019-2024 | Jardiance |
| Pfizer INC. | $524.61 | 2019-2025 | |
| Shockwave Medical, INC | $518.34 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $456.58 | 2019-2024 | Impella |
| Sanofi-Aventis U.S. LLC | $406.39 | 2019-2023 | |
| Biotronik INC. | $403.10 | 2019-2025 | Pantera Leo, Nhancer Rx, Orsiro Mission |
| Cardiovascular Systems INC. | $378.42 | 2021-2023 | Diamondback Coronary, Diamondback Peripheral |
| Abbott Laboratories | $302.95 | 2020-2024 | Dragonfly Opstar |
| Janssen Pharmaceuticals, INC | $294.68 | 2019-2024 | Xarelto |
| Amgen INC. | $220.26 | 2019-2025 | Repatha |
| Kowa Pharmaceuticals America, INC. | $219.07 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $218.18 | 2019-2025 | Lifevest |
| Asahi Intecc USA, INC. | $206.81 | 2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $161.74 | 2022-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $128.13 | 2021-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $121.82 | 2022-2024 | Corevalve Evolut R |
| Scpharmaceuticals INC. | $108.80 | 2023-2025 | |
| Astellas Pharma US INC | $106.00 | 2021-2022 | |
| Recor Medical INC | $100.49 | 2024 | Paradise Renal Denervation System |
| Cvrx, INC. | $97.66 | 2022-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $52.66 | 2022-2025 | Verquvo, Capvaxive |
| Atricure, INC. | $50.40 | 2021-2023 | |
| Irhythm Technologies, INC. | $42.43 | 2020-2021 | |
| Heartflow, INC. | $36.48 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $32.52 | 2019-2024 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $29.57 | 2023 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $24.06 | 2020-2021 | |
| Bardy Diagnostics, INC. | $21.90 | 2019 | |
| Portola Pharmaceuticals, LLC | $20.68 | 2019 | |
| Altathera Pharmaceuticals LLC | $19.96 | 2025 | Sotalol Hydrochloride |
| Lilly USA, LLC | $18.23 | 2024 | Mounjaro |
| Novo Nordisk INC | $17.61 | 2024 | Ozempic |
| Ultragenyx Pharmaceutical INC. | $17.35 | 2023 | |
| Medtronic Vascular, INC. | $17.16 | 2019 | |
| Akcea Therapeutics, INC. | $14.67 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.59 | 2019 | |
| Boston Scientific Corporation | $13.20 | 2019 | |
| Gilead Sciences, INC. | $12.93 | 2019 | |
| Esperion Therapeutics, INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Santora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.